Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Primary objective was to determine efficacy of Alfuzosin in the treatment of children and
adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to
elevated detrusor Leak Point Pressure [LPP] of neuropathic etiology.
Secondary objectives were:
- To investigate the safety and tolerability of alfuzosin 0.2 mg/kg/day in children and
adolescents,
- To investigate the number of Urinary Tract Infection (UTI) episodes,
- To investigate the pharmacokinetics of Alfuzosin (population kinetics).